At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...

The changes will impact millions of people with type 2 diabetes in England in the biggest shake-up of care in a decade ...

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

New draft guidance from the National Institute for Health and Care Excellence suggests the NHS should move away from a one-size-fits-all approach.

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

The new label for Forxiga/Farxiga (dapagliflozin) comes from the DECLARE-TIMI 58 trial, and the EU is the first major market to approve the label update, ahead of the US and China where it remains ...

AstraZeneca's Farxiga (dapagliflozin) for diabetes, heart failure, and chronic kidney disease – down 68% to $178.50; Immunex's Enbrel (aflibercept) for rheumatoid arthritis, psoriasis, and ...